Recently Featured

Mabion Reinitiates MabionCD20 Development via Collaboration with Oddifact for Rare Diseases

June 23, 2026
Mabion S.A., a Polish biotechnology firm, has signed a letter of intent with French TechDev company Oddifact SAS to evaluate and advance MabionCD20 for potential applications in rare diseases. This collaboration signifies the reactivation of Mabion’s CD20 program through a strategic development approach aimed at exploring new clinical indications. The partnership leverages Mabion’s extensive expertise…

China’s Order 818 Establishes New Pathway for Advanced Therapeutics

June 22, 2026
China’s Order 818—Regulations on the Administration of Clinical Research and Clinical Translation and Application of Biomedical New Technologies—establishes a new commercialization pathway for cell and gene therapeutics, gene editing, and other advanced therapeutics. More importantly, it signals China’s intent to accelerate local innovation and standardize the drug development environment, thereby becoming a more important player…

Warning Issued on Promotion of Newly Licensed and Unlicensed Weight Management Medicines

June 22, 2026
The MHRA, Advertising Standards Authority, and the General Pharmaceutical Council have collectively issued a warning to businesses regarding the promotion of newly authorized prescription-only medicines and unlicensed medicines intended for weight management. This advisory comes in light of increasing concerns about the potential for misleading marketing practices that could undermine patient safety and regulatory compliance.…

Ongoing Cases